Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction model for tube feeding dependency during chemoradiotherapy for at least four weeks in head and neck cancer patients: A tool for prophylactic gastrostomy decision making.
Willemsen ACH, Kok A, van Kuijk SMJ, Baijens LWJ, de Bree R, Devriese LA, Hoebers FJP, Lalisang RI, Schols AMWJ, Terhaard CHJ, Hoeben A. Willemsen ACH, et al. Among authors: lalisang ri. Clin Nutr. 2020 Aug;39(8):2600-2608. doi: 10.1016/j.clnu.2019.11.033. Epub 2019 Dec 3. Clin Nutr. 2020. PMID: 31839429
PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.
van Loon J, Even AJG, Aerts HJWL, Öllers M, Hoebers F, van Elmpt W, Dubois L, Dingemans AC, Lalisang RI, Kempers P, Brans B, Winnepenninckx V, Speel EJ, Thunnissen E, Smits KM, Boellaard R, Vugts DJ, De Ruysscher D, Lambin P. van Loon J, et al. Among authors: lalisang ri. Radiother Oncol. 2017 Feb;122(2):267-273. doi: 10.1016/j.radonc.2016.11.020. Epub 2016 Dec 21. Radiother Oncol. 2017. PMID: 28012793 Clinical Trial.
Development and external validation of a prediction model for tube feeding dependency for at least four weeks during chemoradiotherapy for head and neck cancer.
Willemsen ACH, Kok A, Baijens LWJ, de Boer JP, de Bree R, Devriese LA, Driessen CML, van Herpen CML, Hoebers FJP, Kaanders JHAM, Karsten RT, van Kuijk SMJ, Lalisang RI, Navran A, Pereboom SR, Schols AMWJ, Terhaard CHJ, Hoeben A. Willemsen ACH, et al. Among authors: lalisang ri. Clin Nutr. 2022 Jan;41(1):177-185. doi: 10.1016/j.clnu.2021.11.019. Epub 2021 Nov 24. Clin Nutr. 2022. PMID: 34883306 Free article.
Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands.
van der Linden N, Buter J, Pescott CP, Lalisang RI, de Boer JP, de Graeff A, van Herpen CM, Baatenburg de Jong RJ, Uyl-de Groot CA. van der Linden N, et al. Among authors: lalisang ri. Eur Arch Otorhinolaryngol. 2016 Feb;273(2):455-64. doi: 10.1007/s00405-015-3495-y. Epub 2015 Jan 21. Eur Arch Otorhinolaryngol. 2016. PMID: 25876000 Free PMC article.
Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
Post CCB, Westermann AM, Boere IA, Witteveen PO, Ottevanger PB, Sonke GS, Lalisang RI, Putter H, Meershoek-Klein Kranenbarg E, Braak JPBM, Creutzberg CL, Bosse T, Kroep JR. Post CCB, et al. Among authors: lalisang ri. Gynecol Oncol. 2022 May;165(2):223-229. doi: 10.1016/j.ygyno.2022.02.025. Epub 2022 Mar 11. Gynecol Oncol. 2022. PMID: 35287967 Free article. Clinical Trial.
57 results